Search Result

Results for "

striatal

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (8) Adenosine Receptor (1) Adenylate Cyclase (4) Adrenergic Receptor (1) Aminopeptidase (1) Apoptosis (5) Bcl-2 Family (1) Calcium Channel (1) Calpain (1) Caspase (3) Cathepsin (1) Cholinesterase (ChE) (3) COMT (1) COX (2) Deubiquitinase (1) Dopamine Receptor (27) Dopamine Transporter (6) Drug Derivative (2) Endogenous Metabolite (3) ERK (1) GABA Receptor (1) GlyT (1) GPR52 (1) GPR88 (2) Histamine Receptor (1) iGluR (4) Isotope-Labeled Compounds (2) Kallikrein (1) KMO (1) mAChR (3) mGluR (1) Mitophagy (1) Monoamine Oxidase (5) Monoamine Transporter (6) nAChR (5) NO Synthase (2) Opioid Receptor (2) p38 MAPK (1) PARP (3) Phosphodiesterase (PDE) (2) Plasminogen/Plasmin (1) Reference Standards (8) Somatostatin Receptor (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (74)

By Targets:

5-HT Receptor (8)

Adenosine Receptor (1)

Adenylate Cyclase (4)

Adrenergic Receptor (1)

Aminopeptidase (1)

Apoptosis (5)

Bcl-2 Family (1)

Calcium Channel (1)

Calpain (1)

Caspase (3)

Cathepsin (1)

Cholinesterase (ChE) (3)

COMT (1)

COX (2)

Deubiquitinase (1)

Dopamine Receptor (27)

Dopamine Transporter (6)

Drug Derivative (2)

Endogenous Metabolite (3)

ERK (1)

GABA Receptor (1)

GlyT (1)

GPR52 (1)

GPR88 (2)

Histamine Receptor (1)

iGluR (4)

Isotope-Labeled Compounds (2)

Kallikrein (1)

KMO (1)

mAChR (3)

mGluR (1)

Mitophagy (1)

Monoamine Oxidase (5)

Monoamine Transporter (6)

nAChR (5)

NO Synthase (2)

Opioid Receptor (2)

p38 MAPK (1)

PARP (3)

Phosphodiesterase (PDE) (2)

Plasminogen/Plasmin (1)

Reference Standards (8)

Somatostatin Receptor (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (2)

Infection (1)

Inflammation/Immunology (2)

Metabolic Disease (1)

Neurological Disease (74)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-160019

MTX115325	Deubiquitinase Mitophagy	Neurological Disease
MTX115325 (Example 1) is an orally active, brain-penetrating USP30 inhibitor (IC₅₀=12 nM) with neuroprotective activity. MTX115325 increases ubiquitination (EC₅₀=32 nM) of the mitochondrial outer membrane protein TOM20 (a USP30 substrate), increasing mitophagy. MTX115325 prevents dopaminergic neuron loss and preserves striatal dopamine .

HY-B0590

Tetrabenazine 1 Publications Verification Ro 1-9569	Monoamine Transporter Dopamine Receptor	Neurological Disease
Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-12472

Balipodect 2 Publications Verification TAK-063	Phosphodiesterase (PDE)	Infection Neurological Disease Cancer
Balipodect (TAK-063) is a selective, brain-penetrant and orally active PDE10A inhibitor with an IC₅₀ of 0.30 nM. Balipodect shows >15000-fold selectivity over other PDEs. Balipodect elevates striatal cAMP and cGMP levels in mice. Balipodect can be used for the study of schizophrenia_[1].

HY-10435A

SKF-82958 hydrobromide 4 Publications Verification (±)-SKF-82958 hydrobromide; Chloro-APB hydrobromide	Dopamine Receptor	Neurological Disease
SKF-82958 ((±)-SKF 82958) hydrobromide is a dopamine D1 receptor full agonist (K_0.5=4 nM), displays selective for D1 over D2 receptors (K_0.5=73 nM). SKF-82958 hydrobromide induces dopamine D1 receptor-dependent adenylate cyclase activity in rat striatal membranes (EC₅₀=491 nM) .

HY-B0590S

Tetrabenazine-d6 Ro 1-9569-d₆	Monoamine Transporter	Neurological Disease
Tetrabenazine-d₆ (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-B1124

Fipexide 1 Publications Verification	Adenylate Cyclase Dopamine Transporter	Neurological Disease
Fipexide, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide reduces striatal adenylate cyclase activity. Fipexide has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide is used for senile dementia research. Fipexide acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection .

HY-B0344

Methscopolamine bromide 1 Publications Verification (-)-Scopolamine methyl bromide; Hyoscine methyl bromide	mAChR	Neurological Disease
Methscopolamine bromide ((-)-Scopolamine methyl bromide; Hyoscine methyl bromide) is a peripherally acting muscarinic receptor (mAChR) antagonist that cannot cross the blood-brain barrier. Methscopolamine bromide blocks the muscarinic negative feedback regulation of acetylcholine release from striatal cholinergic terminals, thereby increasing acetylcholine release in the striatum of freely moving rats. Methscopolamine bromide does not induce motor excitation in freely moving rats, nor does it alter the duration of ethanol-induced loss of righting reflex in mice. Methscopolamine bromide fails to antagonize the arecoline-mediated reduction in the duration of ethanol-induced loss of righting reflex in mice .

HY-B1382

Pempidine 1,2,2,6,6-Pentamethylpiperidine	nAChR	Cardiovascular Disease Neurological Disease
Pempidine (1,2,2,6,6-Pentamethylpiperidine) is an orally active ganglionic blocking agent used in hypertension-related conditions. Pempidine is a nicotinic receptor blocker. Pempidine can antagonize the nicotine-induced increase of the striatal dopamine (DA) in vitro .

HY-145468

GPR52 antagonist-1	GPR52	Neurological Disease
GPR52 antagonist-1 (Compound 43) is a GPR52 antagonist with an IC₅₀ of 0.63 μM. GPR52 antagonist-1 reduces mHTT (mutant huntingtin protein) levels by targeting GPR52 and promotes survival of mouse primary striatal neurons .

HY-124591

TC-2153	5-HT Receptor Monoamine Oxidase	Neurological Disease
TC-2153 is a selective inhibitor of striatal-enriched protein tyrosine phosphatase (STEP), with psychotropic activity and low acute toxicity. TC-2153 increases the expression of brain-derived neurotropic factor (BDNF) in the brain. And it decreases MAOA and 5-HT1A receptors mRNA level in midbrain. TC-2153 also inhibits 5-HT2A receptor-mediated signaling .

HY-B0188

Mianserin 1 Publications Verification Mianserine	Histamine Receptor Opioid Receptor ERK p38 MAPK	Neurological Disease
Mianserin (Mianserine) is an orally active H1 receptor antagonist. Mianserin can activate κ-opioid receptor and octopamine receptor. Mianserin increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin can be used for the research of neurological disease, such as depression and epilepsy .

HY-145512

N-(α-Linolenoyl) tyrosine NLT	Dopamine Receptor	Neurological Disease
N-(α-Linolenoyl) tyrosine (NLT) is a dopaminergic agonist capable of crossing the blood-brain barrier. N-(α-Linolenoyl) tyrosine increases the level, turnover rate and release amount of dopamine in the striatum. N-(α-Linolenoyl) tyrosine modulates rotational behavior in a rat model with unilateral striatal injury and alleviates excessive blinking symptoms in models induced by dopamine-depleting agents. N-(α-Linolenoyl) tyrosine can be used for research on Parkinson's disease and idiopathic blepharospasm .

HY-Z0283

Benzamide 1 Publications Verification Benzenecarboxamide; Phenylamide	Endogenous Metabolite PARP	Others
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-107969

Haloperidol decanoate	Dopamine Receptor COX NO Synthase	Neurological Disease Cancer
Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity. Haloperidol decanoate can increase the striatal D₂ receptor in rat. Haloperidol decanoate can improve conditions of psychoses (mainly schizophrenia). Haloperidol decanoate can lead to increased accumulation of the dopamine metabolites homo-vanillic acid. Haloperidol decanoate can reduce intestinal transport, increase gastric emptying and reduce acid output in rat model .

HY-167856

RTI-122	GPR88	Neurological Disease
RTI-122 is a selective, blood-brain barrier-permeable GPR88 agonist (cAMP EC₅₀=11 nM), with EC₅₀ values of 11.5 nM and 155 nM for human and mouse GPR88, respectively ([ ³⁵S]GTPγS assay). By activating the GPR88 receptor to regulate the cAMP signaling pathway and G protein activity, RTI-122 significantly attenuates Binge-like drinking, reduces alcohol intake, and decreases alcohol-seeking motivation. RTI-122 blocks the reinstatement of alcohol-seeking behavior without affecting water or sucrose intake. RTI-122 exhibits metabolic stability in mice (T_1/2=5.8 h) and can be used to investigate alcohol use disorder .

HY-159829

Direclidine NBI-1117568; HTL-0016878	mAChR	Neurological Disease
Direclidine (NBI-1117568, HTL-0016878) is a selective orthosteric agonist targeting the muscarinic acetylcholine M4 receptor, exhibiting very low affinity for M1, M2, M3, and M5 receptors. It binds to the orthosteric site of the M4 receptor in a non-covalent, competitive manner. Direclidine specifically activates the M4 receptor, inhibiting the release of acetylcholine from striatal cholinergic interneurons, thereby regulating the balance of the dopaminergic system and reducing psychiatric symptoms associated with excessive dopamine release. Direclidine can improve symptoms associated with neuropsychiatric disorders and is used in research on schizophrenia and other neuropsychiatric disorders .

HY-B1752

Quinpirole 4 Publications Verification LY 171555; (-)-LY 141865	Dopamine Receptor Calcium Channel Bcl-2 Family iGluR Apoptosis	Neurological Disease
Quinpirole (LY 171555; (-)-LY 141865) is a D2/D3 dopamine receptor agonist and a CaV1.3 calcium channel modulator. Quinpirole normalizes dendritic spine density in dopamine-depleted striatum, upregulates the protein expression of BCL2 and GluR2, downregulates the protein expression of BAX, and delays the onset of seizures. Quinpirole enhances learning and memory, inhibits neuronal apoptosis (apoptosis), and induces anxiety-like, stereotyped, and compulsive behaviors. Quinpirole disrupts prepulse inhibition in rhesus monkeys, enhances the activity of paraventricular thalamic neurons to promote recovery from Isoflurane anesthesia, and alters the composition of the gut microbiota in rats. Quinpirole can be used in research related to dyskinesia, pain, epilepsy, and neurological disorders including anxiety disorder, obsessive-compulsive disorder, and schizophrenia .

HY-120017

Befloxatone MD-370503	Monoamine Oxidase	Neurological Disease
Befloxatone (MD-370503) is an orally active, selective and reversible inhibitor of Monoamine Oxidase A (MAO-A) (IC₅₀=4 nM). Befloxatone increases the tissue level of monoamine, striatal dopamine and cortical norepinephrine. Befloxatone has antidepressant potential .

HY-P1206

CH 275 1 Publications Verification	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease .

HY-B0590A

Tetrabenazine Racemate Ro 1-9569 Racemate	Monoamine Transporter Dopamine Receptor	Neurological Disease
Tetrabenazine (Ro 1-9569) Racemate is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine Racemate binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine Racemate weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine Racemate can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-B0884A

Minaprine dihydrochloride	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Minaprine dihydrochloride is a brain-penetrant monoamine oxidase inhibitor. Minaprine dihydrochloride also weakly inhibits acetylcholinesterase (AChE) activity. Minaprine dihydrochloride reduces intraneuronal dopamine metabolism, lowers striatal homovanillic acid and dihydroxyphenylacetic acid levels, and raises striatal 3-methoxytyramine and 5-hydroxytryptamine levels. Minaprine dihydrochloride exhibits convulsant, antidepressant properties .

HY-125339

Ro 41-0960	COMT Apoptosis	Neurological Disease Cancer
Ro 41-0960 is a CNS-penetrant, orally active catechol-O-methyl transferase (COMT) inhibitor. Ro 41-0960 reduces dopamine catabolism, increases striatal dopamine and DOPAC levels, decreases striatal HVA levels, induces apoptosis, inhibits proliferation and extracellular matrix formation in uterine fibroid cells. Ro 41-0960 arrests or shrinks uterine fibroid lesions in rats. Ro 41-0960 can be used for the research of Parkinson’s disease, uterine leiomyomas, and breast cancer .

HY-B1124A

Fipexide hydrochloride 1 Publications Verification	Adenylate Cyclase Dopamine Transporter	Neurological Disease
Fipexide hydrochloride, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide hydrochloride reduces striatal adenylate cyclase activity. Fipexide hydrochloride has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide hydrochloride is used for senile dementia research. Fipexide hydrochloride acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection .

HY-12294A

PEAQX tetrasodium hydrate Maximum Cited Publications 8 Publications Verification NVP-AAM077 tetrasodium hydrate	Apoptosis Caspase iGluR	Neurological Disease
PEAQX tetrasodium hydrate (NVP-AAM077 tetrasodium hydrate) is a tetrasodium hydrate of PEAQX (HY-12294). PEAQX tetrasodium hydrate is an orally active and selective NMDA antagonist, with IC₅₀ values of 270 nM and 29.6 μM for hNMDAR 1A/2A and hNMDAR 1A/2B, respectively. PEAQX tetrasodium hydrate can promote the activation of caspase-3 and induce cell apoptosis in cortical striatal slice cultures .

HY-106584

Mosapramine Clospipramine	Drug Derivative Dopamine Receptor 5-HT Receptor	Neurological Disease
Mosapramine (Clospipramine) is an orally active antipsychotic agent and one of the metabolites of Clocapramine (HY-B2073) after oral absorption. Mosapramine exerts its effects by specifically binding to striatal dopamine D2 receptors and frontal lobe 5-HT2 receptors, with a D2/5-HT2 receptor occupancy ratio of 7.4. Mosapramine induces typical neuropharmacological responses in rat brain regions, including extrapyramidal symptoms, hyperprolactinemia, increased salivation, constipation, and upregulated Fos protein expression. Mosapramine also features a reduced incidence of weight loss. Mosapramine is applicable to research related to schizophrenia .

HY-100968

GBR 12783 dihydrochloride	Dopamine Receptor	Neurological Disease
GBR 12783 dihydrochloride is a specific, potent and selective dopamine uptake inhibitor that inhibits the [ ³H]dopamine uptake by rat and mice striatal synaptosomes with IC₅₀s of 1.8 nM and 1.2 nM, respectively. GBR 12783 dihydrochloride can improve memory performance and increase hippocampal acetylcholine release in rats .

HY-156331

VU6004909	mGluR	Neurological Disease
VU6004909 is a blood-brain barrier penetrated mGlu1 positive allosteric modulator (PAM), with the EC₅₀s of 25.7 nM and 31 nM for human mGlu1 and rat mGlu1, respectively. VU6004909 reduces dorsolateral striatal dopamine (DA) release in vivo and displays antipsychotic efficacy .

HY-12294

PEAQX NVP-AAM077	Caspase Apoptosis iGluR	Neurological Disease
PEAQX (NVP-AAM077) is an orally active and selective NMDA antagonist, with IC₅₀ values of 270 nM and 29.6 μM for hNMDAR 1A/2A and hNMDAR 1A/2B, respectively. PEAQX can promote the activation of caspase-3 and induce cell apoptosis in cortical striatal slice cultures .

HY-P4532

Ac-Leu-Val-Lys-Aldehyde	Cathepsin	Neurological Disease
Ac-Leu-Val-Lys-Aldehyde is a potent cathepsin B inhibitor with IC₅₀s of 4 nM. Ac-Leu-Val-Lys-Aldehyde significantly reduces quinolinic acid (HY-100807)-induced striatal cell death and causes accumulation of LC3-II .

HY-110302

6'-GNTI dihydrochloride	Opioid Receptor	Neurological Disease
6'-GNTI dihydrochloride, a κ-opioid receptor (KOR) agonist, displays bias toward the activation of G protein-mediated signaling over β-arrestin2 recruitment. 6'-GNTI 6'-GNTI dihydrochloride only activates the Akt pathway in striatal neurons .

HY-N2326

(±)-Anatoxin A fumarate	nAChR	Neurological Disease Metabolic Disease
(±)-Anatoxin A fumarate is a natural alkaloid isolated from freshwater cyanobacterium.(±)-Anatoxin A fumarate is a potent nicotinic receptor agonist and exhibits K_i values of 1.25 nM and 1.84 μM for binding to α4β2- and α7-type nicotinic receptors in rat brain membranes, respectively. (±)-Anatoxin A fumarate stimulates [ ³H]-dopamine release from rat striatal synaptosomes (EC₅₀=134 nM). (±)-Anatoxin A fumarate has toxic effect on fish .

HY-156772

GPR88 agonist 2	GPR88	Others Neurological Disease
GPR88 agonist 2 (compound 53) is a potent and brain-penetrantGPR88 agonist with an EC₅₀ value of 14 µM in GPR88 cAMP functional assay .

HY-152170

bPiDI 1 Publications Verification	nAChR	Neurological Disease
bPiDI is a novel selective α6β2 nicotinic receptor antagonist. bPiDI inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .

HY-P1303

CART(62-76)(human,rat)	5-HT Receptor	Neurological Disease
CART(62-76)(human,rat) is a neuropeptide (62-76 residues of the CART peptide) with neurotransmitter-like effects. CART(62-76)(human,rat) can modulate the activity of striatal noradrenergic and corticostriatal and hypothalamic serotoninergic (5-HT) system in the rat brain .

HY-119468

Medifoxamine	Dopamine Transporter	Neurological Disease
Medifoxamine is an orally active monoamine reuptake inhibitor and antidepressant. Medifoxamine preferentially inhibits presynaptic dopamine reuptake. Medifoxamine acts as an intraocular pressure-lowering agent to reduce intraocular pressure, and also functions as a miotic agent to decrease pupil diameter. Medifoxamine exhibits characteristic properties of antidepressant compounds, including preventing hypothermia induced by Reserpine (HY-N0480) or Apomorphine (HY-12723), potentiating the toxic effects of Yohimbine (HY-N0127) in mice, and reducing immobility behavior in mice and rats in the "behavioral despair" model. Medifoxamine has no anticholinergic activity. Medifoxamine can be used in research related to depression .

HY-B0884

Minaprine	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Minaprine is a brain-penetrant monoamine oxidase inhibitor. Minaprine also weakly inhibits acetylcholinesterase (AChE) activity. Minaprine reduces intraneuronal dopamine metabolism, lowers striatal homovanillic acid and dihydroxyphenylacetic acid levels, and raises striatal 3-methoxytyramine and 5-hydroxytryptamine levels. Minaprine exhibits convulsant, antidepressant properties .

HY-107674

bPiDDB	nAChR	Neurological Disease
bPiDDB is a potent nAChR antagonist. bPiDDB potently (IC₅₀=2 nM) inhibits nicotine-evoked striatal dopamine (DA) release through an interaction with α6β2-containing nAChRs .

HY-105328

S-14489	5-HT Receptor	Neurological Disease
S-14489 is an orally active selective postsynaptic 5-HT1A receptor antagonist with a pK_i of 9.2. S-14489 can act as a 5-HT1A autoreceptor agonist and inhibit striatal 5-hydroxytryptophan accumulation. S-14489 can be used for the research of neurological disease .

HY-10435

SKF-82958 (±)-SKF-82958; Chloro-APB	Dopamine Receptor	Neurological Disease
SKF-82958 ((±)-SKF 82958) is a dopamine D1 receptor full agonist (K_0.5=4 nM), displays selective for D1 over D2 receptors (K_0.5=73 nM). SKF-82958 induces dopamine D1 receptor-dependent adenylate cyclase activity in rat striatal membranes (EC₅₀=491 nM) .

HY-W711852

Benzamide-d5 Benzenecarboxamide-d₅; Phenylamide-d₅	Isotope-Labeled Compounds PARP Endogenous Metabolite	Others
Benzamide-d₅ (Benzenecarboxamide-d₅) is deuterium labeled Benzamide. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-118706

PD 118440	Dopamine Receptor	Neurological Disease
PD 118440 is an orally active dopamine (DA) agonist. PD 118440 has significant central nervous system effects, including inhibition of striatal DA synthesis, suppression of DA neuron firing, and reversal of Reserpine (HY-N0480)-induced depression in rats .

HY-12294B

(Rac)-PEAQX (Rac)-NVP-AAM077	iGluR Caspase Apoptosis	Neurological Disease
(Rac)-PEAQX is a NMDA receptor agonist. (Rac)-PEAQX can promote the activation of caspase-3 and induce cell apoptosis in cortical striatal slice cultures .

HY-116550

Piroheptine hydrochloride	Dopamine Transporter	Neurological Disease
Piroheptine hydrochloride is an anticholinergic agent to inhibit dopamine uptake. Piroheptine hydrochloride prevents loss of striatal dopamine induced by MPTP (HY-15608). Piroheptine hydrochloride can be used for research in Parkinson .

HY-118461

PD 120697	Dopamine Receptor	Neurological Disease
PD 120697 is an orally active dopamine (DA) agonist. PD 120697 inhibits striatal DA synthesis, DA neuronal firing, spontaneous locomotor activity, and reverses Reserpine (HY-N0480)-induced depression .

HY-129682

LY125180	5-HT Receptor Dopamine Receptor Adrenergic Receptor	Neurological Disease
LY125180 is a serotonin uptake inhibitor. LY125180 competitively inhibits the uptake of serotonin and norepinephrine by cortical synaptosomes and of dopamine by striatal synaptosomes, with K_i values of 0.06 μM, 2.2 μM and 2.5 μM respectively .

HY-117838

Phosphodiesterase 10-IN-2	Phosphodiesterase (PDE)	Neurological Disease
Phosphodiesterase 10-IN-2 (THPP-4) is an oral active phosphodiesterase 10A (PDE10A) inhibitor with the K_i of 4.5 nM. Phosphodiesterase 10-IN-2 can be used for study of schizophrenia .

HY-W008610

GBR 12783	Dopamine Receptor	Neurological Disease
GBR 12783 is a specific, potent and selective dopamine uptake inhibitor that inhibits the [ ³H]dopamine uptake by rat and mice striatal synaptosomes with IC₅₀s of 1.8 nM and 1.2 nM, respectively. GBR 12783 can improve memory performance and increase hippocampal acetylcholine release in rats .

HY-P1303A

CART(62-76)(human,rat) TFA	5-HT Receptor	Neurological Disease
CART(62-76)(human,rat) TFA is a neuropeptide (62-76 residues of the CART peptide) with neurotransmitter-like effects. CART(62-76)(human,rat) TFA can modulate the activity of striatal noradrenergic and corticostriatal and hypothalamic serotoninergic (5-HT) system in the rat brain .

HY-105793

Mazaticol	mAChR	Neurological Disease
Mazaticol is an anticholinergic agent. Mazaticol blocks the muscarinic acetylcholine receptors and cholinergic nerve activity. Mazaticol is a potent 3H-QNB and 3H-PZ binding inhibitor, can bind to the M2 receptors with high affinity. Mazaticol exhibits inhibitory effects on dopamine uptake in the striatal nerve terminal. Mazaticol can be used for parkinsonian syndrome research .

HY-B1124AR

Fipexide hydrochloride (Standard)	Adenylate Cyclase Dopamine Transporter Reference Standards	Neurological Disease
Fipexide (hydrochloride) (Standard) is the analytical standard of Fipexide (hydrochloride). This product is intended for research and analytical applications. Fipexide hydrochloride, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide hydrochloride reduces striatal adenylate cyclase activity. Fipexide hydrochloride has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide hydrochloride is used for senile dementia research. Fipexide hydrochloride acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection .

Cat. No.	Product Name	Target	Research Area

HY-145512

N-(α-Linolenoyl) tyrosine NLT	Dopamine Receptor	Neurological Disease
N-(α-Linolenoyl) tyrosine (NLT) is a dopaminergic agonist capable of crossing the blood-brain barrier. N-(α-Linolenoyl) tyrosine increases the level, turnover rate and release amount of dopamine in the striatum. N-(α-Linolenoyl) tyrosine modulates rotational behavior in a rat model with unilateral striatal injury and alleviates excessive blinking symptoms in models induced by dopamine-depleting agents. N-(α-Linolenoyl) tyrosine can be used for research on Parkinson's disease and idiopathic blepharospasm .

HY-P1206

CH 275 1 Publications Verification	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease .

HY-P4532

Ac-Leu-Val-Lys-Aldehyde	Cathepsin	Neurological Disease
Ac-Leu-Val-Lys-Aldehyde is a potent cathepsin B inhibitor with IC₅₀s of 4 nM. Ac-Leu-Val-Lys-Aldehyde significantly reduces quinolinic acid (HY-100807)-induced striatal cell death and causes accumulation of LC3-II .

HY-P1303

CART(62-76)(human,rat)	5-HT Receptor	Neurological Disease
CART(62-76)(human,rat) is a neuropeptide (62-76 residues of the CART peptide) with neurotransmitter-like effects. CART(62-76)(human,rat) can modulate the activity of striatal noradrenergic and corticostriatal and hypothalamic serotoninergic (5-HT) system in the rat brain .

HY-P1303A

CART(62-76)(human,rat) TFA	5-HT Receptor	Neurological Disease
CART(62-76)(human,rat) TFA is a neuropeptide (62-76 residues of the CART peptide) with neurotransmitter-like effects. CART(62-76)(human,rat) TFA can modulate the activity of striatal noradrenergic and corticostriatal and hypothalamic serotoninergic (5-HT) system in the rat brain .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-Z0283

Benzamide 1 Publications Verification Benzenecarboxamide; Phenylamide	Alkaloids Human Gut Microbiota Metabolites Classification of Application Fields Other Alkaloids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite PARP
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-Z0283R

Benzamide (Standard) Benzenecarboxamide (Standard); Phenylamide (Standard)	Structural Classification Alkaloids Human Gut Microbiota Metabolites Other Alkaloids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite PARP
Benzamide (Standard) is the analytical standard of Benzamide. This product is intended for research and analytical applications. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

Cat. No.	Product Name	Chemical Structure

HY-B0590S

Tetrabenazine-d6

Tetrabenazine-d₆ (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

HY-W711852

Benzamide-d5

Benzamide-d₅ (Benzenecarboxamide-d₅) is deuterium labeled Benzamide. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-B0590S3

Tetrabenazine-d7

Tetrabenazine-d₇ (TBZ-d₇-d₇) is deuterium labeled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 K_i 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks